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Background: The benefits of a periodic health evaluation remain debatable. The incremental value added by such
evaluations beyond the delivery of age appropriate screening and preventive medicine recommendations is
unclear.
Methods: We retrospectively collected data on a cohort of consecutive patients presenting for their first episode of
a comprehensive periodic health evaluation. We abstracted data on new diagnoses that were identified during this
single episode of care and that were not trivial (i.e., required additional testing or intervention).
Results: The cohort consisted of 491 patients. The rate of new diagnoses per this single episode of care was
0.9 diagnoses per patient. The majority of these diagnoses was not prompted by patients’ complaints (71%) and
would not have been identified by screening guidelines (51%). Men (odds ratio 2.67; 95% CI, 1.76, 4.03) and those
with multiple complaints at presentation (odds ratio 1.12; 95% CI, 1.05, 1.19) were more likely to receive a clinically
relevant diagnosis at the conclusion of the visit. Age was not a predictor of receiving a diagnosis in this cohort.
Conclusion: The first episode of a comprehensive periodic health evaluation may reveal numerous important
diagnoses or risk factors that are not always identified through routine screening.
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The benefits of a periodic health evaluation (PHE) were
first identified in the 1920’s after individuals who
underwent an evaluation to qualify for life insurance
coverage were noted to have decreased mortality [1].
This evaluation has evolved into a traditional annual
PHE with various components that may include obtain-
ing a medical history, physical examination, and labora-
tory testing and may lead to the diagnosis of existing
medical conditions and development of a plan of ac-
tion. This evolution was not driven by any formal
process or documented outcomes [2].
Experts have advocated for the delivery of preventive
services in the context of ongoing clinical care (i.e.,
office visits that are not necessarily dedicated for* Correspondence: kermott.cindy@mayo.edu
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reproduction in any medium, provided the orpreventive care) [3-5]. The importance of delivering pre-
ventive services has been used as a rationale to justify
the PHE [6,7]. A systematic review of the literature
demonstrates that a PHE is consistently associated with
patient receipt of a gynecologic examination, Papanico-
laou smear, cholesterol screening, and fecal occult blood
testing [8]. The PHE had a beneficial effect on patient
worry in one randomized controlled trial [9]. Yet, eco-
nomic realities have transformed the typical general
medical care visit into a shorter, problem-focused visit
that may or may not contain the delivery of preventive
services. Yarnall et al. estimates that to fully satisfy the
United States Preventive Services Task Force (USPSTF)
recommendations in a panel of 2500 patients with an
age and sex distribution similar to that of the US popu-
lation, a total of 1773 hours of a physician's annual time,
or 7.4 hours per working day, are needed [10]. Thus,
preventive medicine measures delivered in this modell Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lack of adequate provider time.
Furthermore, in addition to delivering the appropriate
preventive measures, a PHE may lead to the identification
of symptoms or signs that prompt testing and investiga-
tion, which is referred to as case-finding. Patients fre-
quently use their annual exam or PHE to bring up
complaints and concerns they have “saved” to be
addressed on that day. The benefits of delivering prevent-
ive measures and case findings should be balanced against
cost, harms associated with diagnostic interventions, and
known challenges that relate to the early identification of
conditions that have slow progression with minimal bene-
fit attributed to early diagnosis and treatment.
The purpose of this study is to evaluate the diagnostic
yield of the first episode of a comprehensive medical
evaluation in patients seeking a preventive evaluation.
The study will provide prevalence data of new, previ-
ously undiagnosed, medical conditions and risk factors
that are expected to be encountered in the first episode
in such a setting.
Methods
We collected data on a sample of 500 consecutive new
patients presenting for their first episode of a comprehen-
sive PHE. For the purposes of this study, an episode is
defined as an initial visit and one or more follow up visits
to review results of testing. Patients were adults enrolled
in an Executive Health Program designed to provide
health services and evaluation of ongoing medical condi-
tions to employer-sponsored individuals. Patients may or
may not have primary care providers with whom they fol-
low on a regular basis. The examination includes an initial
60 minute visit with a physician, electrocardiogram, and
laboratory testing that consists of urinalysis, complete
blood count, and basic chemistry tests (e.g., serum glu-
cose, lipids, and liver, kidney and thyroid function tests).
Physicians also provide additional testing based on
patients’ symptoms, risk factors, personal and family his-
tory; and deliver immunizations and screening tests. Phy-
sicians meet for a second time with patients to discuss test
results and to provide education and counseling (this is a
shorter visit that averages 15–20 minutes and typically
takes place the following day). The executive health cohort
has a mean age of 52 years with a majority of men (68%)
and a high level of education (80% with education of 4-
year college or higher). The characteristics of the whole
cohort, from which this sample is derived, have been
described in detail elsewhere [11].
Trained nurse data abstractors recorded the diagnoses
listed in the medical record after the conclusion of the
medical episode (i.e., after the second or final encoun-
ter). Diagnoses were extracted from the medical notes as
dictated by physicians. To determine the yield of thismedical evaluation, existing diagnoses, defined as those
reported by the patient or noted in available medical
records either brought by the patient or obtained by the
physician during the course of the evaluation, were
excluded. Only new disease diagnoses detected during
this evaluation were analyzed, along with all potential
significant risk factors for developing a disease.
Given a lack of valid and reliable scales to grade the
clinical importance of diagnoses encountered in out-
patient settings, three physicians independently rated the
importance of diagnoses and excluded trivial ones (e.g., re-
fraction disorders, cerumen impaction, cherry angiomata,
excessive caffeine intake, seborrheic keratosis, skin tags
and skin telangiectasias, etc.). Agreement among the three
raters was assessed by estimating the intraclass correlation
coefficient (ICC) in a random sample of 44 diagnoses. The
ICC can be used to assess agreement among multiple
raters and can be interpreted similarly to Kappa (≥ 0.75 is
consistent with good agreement, 0.40-0.75 is consistent
with fair agreement, and ≥ 0.4 is consistent with poor
agreement). In the random sample, the agreement was ex-
cellent (0.94; 95% Confidence Interval (CI), 0.91, 0.97).
Each diagnosis was classified as either patient
prompted (i.e., patient reported symptoms related to the
diagnosis) or non-patient prompted (i.e., identified by
data gathered from the comprehensive history and
examination, as well as from age and gender appropriate
laboratory investigations and USPSTF screening recom-
mendations). We estimated the odds ratio (OR) and 95%
CI of having at least one diagnosis using logistic regres-
sion with three explanatory variables, sex, age, and num-
ber of concerns or complaints listed on the admission
intake form filled by patients.
The study was approved by the Mayo Clinic Institu-
tional Review Board, Rochester, Minnesota. Only
patients who had consented to have their medical record
data used for research purposes were included. All ana-
lyses were performed using SAS 9.2 version software.
Results
Of the 500 eligible consecutive new patients enrolled in
the program and presenting for their first episode of care,
nine refused release of their record for research, leaving
491 patients in the study population (351 men and 140
women). The cohort was diagnosed with 428 new and
clinically important diagnoses (mean of 0.9 diagnoses per
patient); these are further categorized below. Patients’ age
in this cohort averaged 47 years (range 20–77 years). Of
the 428 new diagnoses, 82% (350/428) were in men and
18% (78/428) in women. The characteristics of included
patients are described in Table 1.
These diagnoses were given to 260 unique patients
(53% of all patients) with a mean of 1.6 diagnoses per
patient. On further breakdown, 139 patients had one
Table 1 Baseline demographics of study cohort
Variable Overall No new clinically important diagnoses New clinically important diagnoses P
Value(N= 491) (N= 240) (N= 251)
Age, years (± 1 SD) 50.7 (± 9.5) 50.7 (± 9.3) 50.7 (± 9.7) 1
Concern, n (± 1 SD) 5.7 (± 3.4) 5.2 (± 2.9) 6.2 (± 3.8) <.001
Diagnoses, n (± 1 SD) 9.8 (± 4.0) 1.6 (± 0.9) <.001
Gender, n (%) <.001
Female 140 (29) 88 (37) 52 (21)
Male 351 (71) 152 (63) 199 (79)
Age ranges, n (%) 0.64
20-39 59 (12) 32 (13) 27 (11)
40-64 401 (82) 194 (81) 207 (82)
65+ 31 (6) 14 (6) 17 (7)
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four, 1 had five, 1 had six, and 1 had eight. The preva-
lence of diagnoses is described in Table 2.
Of 428 new diagnoses, 124 were patient prompted,
while 304 (71%) were non-patient prompted and identi-
fied through PHE screening investigations (laboratory
tests, USPSTF recommended screening tests (mammo-
gram, colonoscopy etc.) and physician evaluation (e.g.
identification of a finding on physical examination that
led to a new diagnosis). The highest prevalence of new
diagnoses was found in endocrine disorders (184) with
only 10 of 174 being patient prompted. Higher rates of
diagnoses which were not patient prompted were also
noted in the categories of malignancy, cardiovascular
and gastrointestinal diseases. Nicotine dependency was
not patient-prompted in 2 of 41 individuals who were
nicotine-dependent, and alcohol abuse was not patient-
prompted in 1 of 4 individuals with alcohol abuse.
Of the 428 diagnoses found, 401 (94%) had no corre-
sponding USPSTF recommendation for screening. Only
9 diagnoses were detected on the basis of USPSTF
recommendations grade A or B (i.e., services that should
be offered).
Logistic regression demonstrated that the predictors of
being diagnosed with at least one diagnosis were male
sex (OR 2.67; 95% CI, 1.76, 4.03) and the number of
concerns or complaints listed on the admission intake
form filled by patients (OR 1.12; 95% CI, 1.05, 1.19) but
not age; see Table 3.
Discussion
We conducted a retrospective chart review to determine
the diagnostic yield of the first episode of a comprehensive
prevention-focused PHE. We demonstrated that even in
healthy, employed patients, numerous conditions can be
identified, some of which may be serious or require add-
itional evaluation and treatment (e.g., pituitary adenomathat may be functional or aortic aneurysm that requires
serial monitoring or treatment). This study provides the
prevalence estimates of various conditions including malig-
nancies, endocrinopathies, cardiovascular, renal, gastro-
intestinal, neurologic, and ophthalmologic diseases
encountered in this setting. Men and those with multiple
complaints at presentation were more likely to receive a
clinically relevant diagnosis at the conclusion of the visit.
Age was not a predictor in this cohort.
More than half of the clinically significant diagnoses in
our study may have been missed without a comprehen-
sive screening strategy, as these had been neither patient
prompted nor discoverable by typical USPSTF screening
strategies.
Nicotine dependence and alcohol abuse, when diag-
nosed, had only been self-identified as a problem by
some, but not all affected patients. This underscores the
importance of proactively addressing these habits with
the patient to support healthy lifestyle change, poten-
tially avoiding long-term health consequences. The same
is true of obesity, as 90% of those with class III obesity
(BMI greater than 40) similarly did not identify weight
as a significant health problem.
Our results are consistent with a trial by Fletcher et al.
[12] in which the authors tested an approach of active
multiphasic screening and case finding examinations
that consisted of history, examination, urinalysis, basic
chemistry, complete blood count, chest x-ray, electrocar-
diogram, pulmonary function testing, and audiometry.
The case finding group had significantly more diagnoses
than a control group (77 new diagnoses in 36 patients or
2.14 diagnoses per participant, of which, 25 were consid-
ered important (0.69 diagnosis per participant). Follow
up one year later, demonstrated that intervention or
change in medical care was required for 40% of these
new diagnoses. Fletcher et al. argues that their study
refutes the claim that if physicians were truly providing
Table 2 Prevalence of diagnoses
Categories Prevalence, n (%)N=491 No. Not Patient Prompted USPSTFRecommendationsfor Screening
ENDOCRINE
Adrenal adenoma 2 (0.4) 2 NR
Diabetes mellitus Type 2 3 (0.6) 3 B*
Dyslipidemia 40 (8.2) 40 A**
Chronic fatigue 1 (0.2) 1 NR
Hyperparathyroidism 6 (1.2) 6 NR
Hyperthyroidism 2 (0.4) 2 I
Elevated lipoprotein (a) 12 (2.4) 12 NR
Metabolic syndrome 6 (1.2) 6 NR
Obesity 95 (19.4) 88 B
Class I 72 67
Class II 13 12
Class III 10 9
Osteoporosis 9 (1.8) 8 B
Thyroid nodule 4 (0.8) 2 I
Hashimoto’s thyroiditis 1 (0.2) 1 I
Thyrotoxicosis 1 (0.2) 1 I
Vertebral compression fracture 2 (0.4) 2 NR
TOTAL 184 (37.4) 174
MALIGNANCY
Non-melanoma skin 8 (1.6) 8 I
Melanoma 7 (1.4) 4 I
Prostate cancer 4 (0.8) 4 D
Renal cell carcinoma 1 (0.2) 1 NR
Pancreatic cancer 1 (0.2) 0 D
TOTAL 21 (4.2) 17
PRE-MALIGNANT
Colon polyp (large, multiple, tubulovillous+) 5 (1.0) 5 A
PSA elevation 6 (1.2) 6 D
Night sweats 2 (0.4) 0 NR
TOTAL 13 (2.6) 11
CARDIOVASCULAR
Aortic aneurysm, thoracic 1 (0.2) 1 NR
Aortic aneurysm, abdominal 1 (0.2) 1 B
Aortic dilatation (any area) 2 (0.4) 2 NR
Moderate aortic stenosis 1 (0.2) 1 NR
Aortic valve regurgitation 2 (0.4) 2 NR
Bicuspid aortic valve 1 (0.2) 1 NR
CAD, stable 3 (0.6) 3 D
CAD, unstable 1 (0.2) 0 NR
Chest pain 4 (0.8) 3 NR
LVH 2 (0.4) 2 NR
Patent foramen ovale 1 (0.2) 1 NR
Abnormal stress test 2 (0.4) 2 D, I***
Kermott et al. BMC Health Services Research 2012, 12:137 Page 4 of 8
http://www.biomedcentral.com/1472-6963/12/137
Table 2 Prevalence of diagnoses (Continued)
Congestive heart failure 1 (0.2) 0 NR
Peripheral artery disease 1 (0.2) 0 D
TOTAL 23 (4.6) 19
GASTROENTEROLOGY
Barrett’s esophagus 1 (0.2) 1 NR
Crohn’s disease 1 (0.2) 1 NR
Diverticulitis 4 (0.8) 3 NR
Diverticulosis 1 (0.2) 1 NR
Esophagitis 6 (1.2) 5 NR
Helicobacter pylori 4 (0.8) 3 NR
Hemochromatosis 1 (0.2) 1 D
Hepatitis C 1 (0.2) 1 D
Splenomegaly 2 (0.4) 2 NR
Steatohepatitis 8 (1.6) 8 NR
Mesenteric abscess 1 (0.2) 0 NR
Hematochezia 2 (0.4) 0 NR
TOTAL 32 (6.4) 25
NEUROLOGY
Cerebral infarction 1 (0.2) 0 NR
Lumbar stenosis 1 (0.2) 1 NR
Neuropathy 6 (1.2) 2 NR
Paresthesia 12 (2.4) 4 NR
Pituitary adenoma 1 (0.2) 1 NR
Seizure 1 (0.2) 1 NR
Syringomyelia 1 (0.2) 1 NR
Spinal syrinx 1 (0.2) 1 NR
Gliomatosis cerebri 1 (0.2) 0 NR
Transient ischemic attack 1 (0.2) 0 NR
TOTAL 26 (5.2) 11
PULMONARY
COPD 3 (0.6) 3 D
Obstructive sleep apnea 24 (4.9) 11 NR
Pleural effusion 1 (0.2) 1 I
Pleural thickening 1 (0.2) 1 I
Pneumonitis 2 (0.4) 2 NR
Upper airway resistance 1 (0.2) 1 NR
Asthma 1 (0.2) 0 NR
LTBI 1 (0.2) 1 NR
TOTAL 34 (6.9) 20
NEPHROLOGY
IGA nephropathy 1 (0.2) 1 NR
Medullary sponge kidney 1 (0.2) 1 NR
Nephrolithiasis 3 (0.6) 2 NR
Polycystic kidney disease 2 (0.4) 2 NR
Prerenal azotemia 1 (0.2) 1 NR
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Table 2 Prevalence of diagnoses (Continued)
Renal insufficiency 3 (0.6) 3 NR
TOTAL 11 (2.2) 10
OPHTHALMOLOGY
Macular degeneration 3 (0.6) 3 NR
Glaucoma 4 (0.8) 4 I
Diabetic retinopathy 1 (0.2) 1 NR
TOTAL 8 (1.6) 8
PSYCHIATRIC
Depression 9 (1.8) 1 B
Eating disorder 1 (0.2) 1 NR
Adjustment disorder 2 (0.4) 0 NR
Anxiety 8 (1.6) 1 NR
TOTAL 20 (4.0) 3
HEALTH HABITS
Alcohol abuse 5 (1.0) 1 B
Nicotine dependency 43 (8.8) 2 A
TOTAL 48 (9.8) 3
OTHER
Hearing loss (severe/asymmetric) 5 (1.0) 3 NR
Seronegative spondyloarthropathy 1 (0.2) 0 NR
Infertility 1 (0.2) 0 NR
Otitis media 1 (0.2) 0 NR
TOTAL 8 (1.6) 3
TOTAL 428 (87.0) 304
Abbreviations: PSA, prostatic surface antigen; CAD, coronary artery disease; LVH, left ventricular hypertrophy; LTBI, Latent Tuberculosis Infection; COPD, chronic
obstructive pulmonary disease; USPSTF, United States Preventive Services Task Force.
Recommendations for average risk patient are considered Grade A- Strongly recommended; Grade B- Recommended; Grade C- No recommendation; Grade D-
Recommend against routine use; Grade I- Insufficient evidence to recommend for or against the intervention; NR- No recommendation available.
*Screen in individuals with hypertension, 2 out of 3 individuals met this criteria.
**Screen for men age ±35 and women age ±45.
***D for adults with low risk; I for adults with increased risk for coronary heart disease. ^ elevated PSA did not result in diagnosis of prostate cancer.
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need for additional multiphasic screening [12].
In addition to increased delivery of preventive services
[8], PHEs can be associated with improvements in sev-
eral other patient-important outcomes. Friedman et al.
[13] conducted a randomized controlled trial in which
annual examinations were provided to 5,156 men and
women age 35–54 (average of 6.8 exams over 16 years)
and compared their outcomes to a control group. The
study group had a 30% reduction in mortality due to
pre-specified potentially preventable or treatable condi-
tions (mainly colorectal cancer and hypertension). Pat-
rick et al. [9] compared the outcomes of usual care to a
preventive services benefit package that included a
health risk assessment, a health promotion visit, a dis-
ease prevention visit, and a follow up visit. They demon-
strated that Medicare beneficiaries randomized to the
intervention group completed more advance directives,participated in more exercise, consumed less dietary fat,
and reported higher satisfaction with health, less decline
in self-rated health status, and fewer depressive
symptoms.
The findings of this descriptive study may not be
generalizable to other practice models or patient popula-
tions. It is likely that we underestimated the prevalence
of multiple conditions because our population is likely
to have higher socioeconomic and educational status,
and to be gainfully employed with better access to health
care. Thus, a higher yield of diagnoses would be antici-
pated in more diverse populations with fewer resources
or contact with the health care system. We did not
evaluate patients’ prior experiences with care they
received in primary care settings elsewhere. Such care
may dictate the frequency of more detailed evaluations
like the one we presented in this cohort. In a previous
study, a 6889 patient sample from the same cohort [11],
Table 3 Logistic regression model to predict presence of





Male sex 2.7 1.8 4.0 <.0001
No of concerns at presentation 1.1 1.1 1.2 0.0002
Age 1.0 1.0 1.0 0.5706
Kermott et al. BMC Health Services Research 2012, 12:137 Page 7 of 8
http://www.biomedcentral.com/1472-6963/12/137we demonstrated fair, although variable, adherence to
preventive recommendations (ranging 62%-91%).
Further, it is unclear whether the early diagnosis of
many conditions identified in this cohort is cost effective
or associated with improved survival and quality of life.
It is also important to recognize that the evidence sup-
porting benefits of PHEs is hampered by the heterogen-
eity of the interventions (i.e., the components and
variability of the health evaluations) and with the mixed
results reported in the areas of costs, disability preven-
tion, and hospitalization [8]. The results of this report
should not be interpreted as evidence against the
USPSTF recommendations nor does it suggest more ag-
gressive screening strategies. Rather, these findings sup-
port a more comprehensive evaluation. The PHE is a
valuable service which facilitates implementing USPSTF
recommendations and increases the diagnostic yield of
other underlying conditions. This study is not compara-
tive. Therefore, we do not claim superior diagnostic abil-
ity over alternative strategies. This study does not
evaluate the relative efficacy of the components of the
comprehensive evaluation as these can vary according to
the unique disease entity. This report also draws atten-
tion to the lack of reliable scales, rating systems, and
taxonomy that aids in categorizing the importance of
diagnoses encountered in outpatient settings. In the
medical literature various descriptions of diagnoses exist,
such as “patient-important,” “clinically-important,” “re-
quiring medical attention,” “requiring follow up,” and
many others. We believe that the establishment of a
scale or rating system will inform the design of out-
patient practices and the development of clinical practice
guidelines.
In summary, this study demonstrates that a comprehen-
sive medical evaluation identifies numerous clinically im-
portant conditions that may affect the way patients feel,
live and survive, that would not have been diagnosed
otherwise. While our findings may not be compelling for
policymakers to recommend such an intervention for all
individuals, those with values and preferences consistent
with the desire for early detection and intervention will
likely opt to have a comprehensive PHE. Patients who
schedule periodic, often annual, evaluations with their
health care provider or present to executive health pro-
grams are likely self-selected for such inherent values andpreferences. Therefore, providing these individuals with
the option of a periodic comprehensive examination
would be consistent with their values and with the second
principle of evidence-based medicine (Evidence alone is
never sufficient to make a clinical decision. Patients’ values
and preferences should always be considered) [14]. Add-
itionally, when patient fears and anxieties are adequately
addressed, unnecessary testing and excessive utilization of
the health care system may be avoided. Data from this
study may help with the planning and design of outpatient
practices, in addition to shaping both patient and provider
expectations of these types of medical encounters.
Conclusions
The first episode of a comprehensive PHE may reveal
numerous important diagnoses or risk factors that are
not always identified through routine screening. The
PHE that includes a comprehensive medical history and
physical examination remains a valuable tool in out-
patient practice.
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